Drugs / N,N-dimethyltryptamine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06899334 | Apr 2025 → Aug 2026 overdue | — | University Hospital, Basel, Switzerland | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | N,N-dimethyltryptamine | “Lysergic acid diethylamide (LSD), psilocybin, and N,N-dimethyltryptamine (DMT) are serotonergic hallucinogens (psychedelics)” NCT06899334 ↗ |
| Known as | DMT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06899334 ↗ |
| Route | Intravenous | “A moderate to high, dose-escalating, intravenous infusion up to 2 mg/min DMT will be administered” NCT06899334 ↗ |